BRAF and melanoma: Importantly, melanoma cells with this mutation were found to be more sensitive to B-RAF inhibitors, and in 2011, the FDA approved the use of vemurafenib for the treatment of B-RAF V600E-positive melanomas, making it the first drug designed using fragment-based lead discovery to gain regulatory approval [38].